Gilead Sciences (GILD) Shares Sold by Tekla Capital Management LLC

Tekla Capital Management LLC lessened its stake in Gilead Sciences (NASDAQ:GILD) by 10.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,520,281 shares of the biopharmaceutical company’s stock after selling 280,850 shares during the quarter. Gilead Sciences comprises 7.0% of Tekla Capital Management LLC’s investment portfolio, making the stock its biggest position. Tekla Capital Management LLC owned 0.19% of Gilead Sciences worth $180,553,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Capital International Investors raised its stake in Gilead Sciences by 86.6% during the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock worth $908,803,000 after acquiring an additional 5,205,983 shares in the last quarter. Sanders Capital LLC raised its stake in Gilead Sciences by 102.9% during the fourth quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock worth $757,119,000 after acquiring an additional 5,026,015 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in Gilead Sciences by 230.0% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock worth $399,233,000 after acquiring an additional 3,434,450 shares in the last quarter. CI Global Investments Inc. raised its stake in Gilead Sciences by 5,461.1% during the fourth quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock worth $237,675,000 after acquiring an additional 3,257,969 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. raised its stake in Gilead Sciences by 53.3% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 9,054,685 shares of the biopharmaceutical company’s stock worth $648,679,000 after acquiring an additional 3,148,128 shares in the last quarter. 78.35% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In related news, Director Gayle E. Wilson sold 60,000 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $77.92, for a total value of $4,675,200.00. Following the sale, the director now directly owns 182,258 shares in the company, valued at $14,201,543.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $83.51, for a total value of $2,087,750.00. Following the completion of the sale, the executive vice president now owns 62,738 shares in the company, valued at $5,239,250.38. The disclosure for this sale can be found here. Insiders sold 308,600 shares of company stock valued at $24,328,226 in the last ninety days. 1.16% of the stock is currently owned by insiders.



GILD has been the subject of several research analyst reports. Credit Suisse Group downgraded Gilead Sciences from an “outperform” rating to a “neutral” rating and boosted their target price for the stock from $74.35 to $80.00 in a research note on Wednesday, December 20th. Oppenheimer reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, December 21st. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. BMO Capital Markets reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, January 3rd. Finally, BidaskClub downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus price target of $88.61.

Gilead Sciences stock opened at $74.69 on Tuesday. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. The company has a market capitalization of $98,075.59, a PE ratio of 8.73, a PEG ratio of -1.73 and a beta of 1.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the prior year, the firm posted $2.70 earnings per share. The firm’s revenue was down 18.7% compared to the same quarter last year. sell-side analysts predict that Gilead Sciences will post 6.21 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were paid a $0.57 dividend. The ex-dividend date was Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 3.05%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is currently 26.64%.

ILLEGAL ACTIVITY WARNING: This article was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://stocknewstimes.com/2018/04/17/gilead-sciences-gild-shares-sold-by-tekla-capital-management-llc.html.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply